Stockreport

JCR Pharmaceuticals Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA [Yahoo! Finance]

ITOCHU CORP UNSP/ADR  (ITOCY) 
NASDAQ:AMEX Investor Relations: itochu.co.jp/en/ir/index.html
PDF in Japan in the Phase I clinical trial of JR-441, an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, also know [Read more]